Tango Therapeutics (NASDAQ:TNGX) Insider Adam Crystal Sells 54,345 Shares of Stock

Tango Therapeutics, Inc. (NASDAQ:TNGX) insider Adam Crystal sold 54,345 shares of the company’s stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $12.77, for a total transaction of $693,985.65. Following the completion of the sale, the insider owned 132,873 shares in the company, valued at approximately $1,696,788.21. This trade represents a 29.03% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Adam Crystal also recently made the following trade(s):

• On Tuesday, February 3rd, Adam Crystal sold 18,452 shares of Tango Therapeutics stock. The stock was sold at an average price of $12.26, for a total transaction of $226,221.52.

Tango Therapeutics Stock Down 2.3%

Shares of NASDAQ TNGX opened at $11.14 on Friday. The stock has a market capitalization of $1.50 billion, a P/E ratio of -11.98 and a beta of 1.75. The firm’s 50-day moving average price is $11.35 and its two-hundred day moving average price is $9.20. Tango Therapeutics, Inc. has a 52-week low of $1.03 and a 52-week high of $13.60.

Hedge Funds Weigh In On Tango Therapeutics

A number of institutional investors have recently made changes to their positions in TNGX. Seven Fleet Capital Management LP bought a new stake in Tango Therapeutics during the 4th quarter valued at approximately $1,906,000. XTX Topco Ltd bought a new position in Tango Therapeutics in the 4th quarter worth approximately $335,000. VARCOV Co. acquired a new position in shares of Tango Therapeutics during the fourth quarter worth approximately $261,000. Virtus Investment Advisers LLC boosted its position in shares of Tango Therapeutics by 26.3% in the fourth quarter. Virtus Investment Advisers LLC now owns 28,452 shares of the company’s stock valued at $252,000 after acquiring an additional 5,920 shares during the period. Finally, Tudor Investment Corp ET AL grew its stake in shares of Tango Therapeutics by 27.4% in the fourth quarter. Tudor Investment Corp ET AL now owns 68,251 shares of the company’s stock worth $605,000 after acquiring an additional 14,679 shares during the last quarter. 78.99% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. Stifel Nicolaus started coverage on Tango Therapeutics in a report on Wednesday, December 3rd. They set a “buy” rating and a $15.00 price target on the stock. B. Riley Financial increased their target price on shares of Tango Therapeutics from $8.00 to $14.00 and gave the company a “buy” rating in a research note on Tuesday, November 18th. Mizuho began coverage on Tango Therapeutics in a research report on Monday, February 23rd. They issued an “outperform” rating and a $19.00 price target for the company. Wall Street Zen raised shares of Tango Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, December 13th. Finally, Guggenheim increased their price target on shares of Tango Therapeutics from $12.00 to $18.00 and gave the stock a “buy” rating in a research report on Friday, February 6th. Seven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $15.50.

Tango Therapeutics Company Profile

Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.

The company’s lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues.